Reviewing: Monoclonal Antibody Therapies Targeting IL-6 & TNF-Alpha against Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint damage with inflammation, significantly affecting the overall quality of life.Monoclonal antibody (mAbs) therapies have updated the management of RA by targeting key inflammatory pathways like tumor necrosis factor (TNF)-α and interleukin-6 (IL-6) due to their efficacy and safety profile compared to synthetic drugs.Thus, this review comprehensively investigates the mechanism of action, efficacy, and safety profile of various mAbs (TNF-α and IL-6 inhibitors).This review found significant therapeutic outcomes, like symptom alleviation, disease progression, remission rate, and safety profiles of TNF inhibitors (etanercept, adalimumab, and infliximab), and IL-6 inhibitors (tocilizumab and sarilumab).Furthermore, this review also explores adverse events and economic considerations associated with these mAbs, which can influence clinical decision-making.By synthesizing this evidence, clinicians can enhance RA management and tailor the treatment plan to individual needs.